Quick Answer
Vicapsys Life Sciences, Inc. reported R&D Expense of $15.3 thousand for fiscal year 2023.
Vicapsys Life Sciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2023 | $15.3K | +16.6% |
| 2022 | $13.1K | -26.0% |
| 2021 | $17.7K | -82.7% |
| 2020 | $102.2K | +3.2% |
| 2019 | $99.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $3.7K | +14.7% | -62.5% |
| June 30, 2024 | $10.0K | +400.0% | +2807.0% |
| March 31, 2024 | $344.00 | -96.6% | -89.5% |
| September 30, 2023 | $3.3K | +5.5% | +63.3% |
| June 30, 2023 | $2.0K | — | -80.0% |
| March 31, 2023 | $10.0K | +0.0% | +222.9% |
| September 30, 2022 | $3.1K | — | -69.0% |
| March 31, 2022 | $10.0K | +333.5% | +102.6% |
- Vicapsys Life Sciences, Inc. showed an increase of +16.6% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2023 period, Vicapsys Life Sciences, Inc.’s r&d expense has declined by 84.6% (from $99.0 thousand to $15.3 thousand).
- The most recent figure is from Vicapsys Life Sciences, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on October 21, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: